{"id":27038,"date":"2024-12-27T17:30:09","date_gmt":"2024-12-28T00:30:09","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=27038"},"modified":"2024-12-27T17:30:12","modified_gmt":"2024-12-28T00:30:12","slug":"ivig-for-immune-checkpoint-inhibitor-related-toxicity","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/","title":{"rendered":"IgIV para la toxicidad relacionada con los inhibidores de los puntos de control inmunitario"},"content":{"rendered":"<p><a href=\"https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/checkpoint-inhibitors\">Inhibidores de los puntos de control inmunitario (ICI)<\/a> Son potentes agentes farmacol\u00f3gicos que estimulan respuestas inmunitarias duraderas contra el c\u00e1ncer. La inmunoterapia ICI ha revolucionado los procedimientos de tratamiento del c\u00e1ncer y ahora se ha convertido en una opci\u00f3n eficaz para pacientes con c\u00e1nceres avanzados o dif\u00edciles de tratar (agresivos).&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-8e3819037161d6b314e6c3293442a708\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tConsulte a un especialista en IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p>Sin embargo, estos agentes anticancer\u00edgenos a veces pueden sobreestimular la respuesta inmune y causar varios efectos adversos, tambi\u00e9n conocidos como <a href=\"https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2024.1447021\/full\">eventos adversos relacionados con el sistema inmunitario (irAEs) o toxicidad relacionada con inhibidores de puntos de control inmunitario<\/a>La toxicidad relacionada con ICI puede afectar a todos los \u00f3rganos, pero la piel, el sistema digestivo y los \u00f3rganos endocrinos son los m\u00e1s frecuentemente afectados.&nbsp;<\/p>\n\n\n\n<p>Si usted o alguien que conoce est\u00e1 experimentando una toxicidad relacionada con los puntos de control inmunitario de grave a moderada, entonces <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-brand-reviews\/\">Terapia con IgIV<\/a> Se puede considerar la administraci\u00f3n de IgIV para controlar estas toxicidades (o reacciones adversas relacionadas con la inmunidad). Este art\u00edculo explica brevemente qu\u00e9 son los inhibidores de puntos de control inmunitario, las toxicidades que causan y c\u00f3mo la IgIV puede ayudar a controlarlas.&nbsp;<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#What_Are_Immune_Checkpoint_Inhibitors\" >\u00bfQu\u00e9 son los inhibidores de puntos de control inmunitario?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#What_Is_Immune-Checkpoint_Inhibitor-Related_Toxicity\" >\u00bfQu\u00e9 es la toxicidad relacionada con los inhibidores de puntos de control inmunitario?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#How_Is_Immune_Checkpoint_Inhibitor-Related_Toxicity_Managed\" >\u00bfC\u00f3mo se maneja la toxicidad relacionada con los inhibidores de puntos de control inmunitario?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#How_Can_IVIG_Manage_Immune_Checkpoint_Inhibitor-Related_Toxicity\" >\u00bfC\u00f3mo puede la IgIV controlar la toxicidad relacionada con los inhibidores de los puntos de control inmunitario?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#It_Neutralizes_Autoantibodies\" >Neutraliza los autoanticuerpos&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#It_Reduces_Inflammation\" >Reduce la inflamaci\u00f3n<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#It_Prevents_Tissue_Damage\" >Previene el da\u00f1o tisular<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#When_Is_IVIG_Used_for_Immune_Checkpoint_Inhibitor-Related_Toxicity\" >\u00bfCu\u00e1ndo se utiliza la IgIV para la toxicidad relacionada con los inhibidores de los puntos de control inmunitario?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#Why_Is_IVIG_Considered_for_Immune_Checkpoint_Inhibitor-Related_Toxicity\" >\u00bfPor qu\u00e9 se considera la IgIV en casos de toxicidad relacionada con los inhibidores de puntos de control inmunitario?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#What_Is_the_Standard_Dose_of_IVIG_for_Immune_Checkpoint_Inhibitor-Related_Toxicity\" >\u00bfCu\u00e1l es la dosis est\u00e1ndar de IgIV para la toxicidad relacionada con los inhibidores de puntos de control inmunitario?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#Conclusion\" >Conclusi\u00f3n<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-what-are-immune-checkpoint-inhibitors\"><span class=\"ez-toc-section\" id=\"What_Are_Immune_Checkpoint_Inhibitors\"><\/span><strong>\u00bfQu\u00e9 son los inhibidores de puntos de control inmunitario?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Normalmente, su sistema inmunol\u00f3gico tiene <a href=\"https:\/\/www.nature.com\/articles\/s41422-020-0343-4\">puntos de control inmunitario<\/a>, que son las prote\u00ednas que act\u00faan como freno para evitar que las c\u00e9lulas inmunitarias ataquen a las c\u00e9lulas sanas. Sin embargo, algunas c\u00e9lulas cancerosas pueden evadir la destrucci\u00f3n produciendo sus propias prote\u00ednas de punto de control.<\/p>\n\n\n\n<p>Cuando las prote\u00ednas de control de una c\u00e9lula cancerosa se unen a las prote\u00ednas de control de las c\u00e9lulas T, desactivan a las c\u00e9lulas T; como resultado, las c\u00e9lulas cancerosas contin\u00faan creciendo y propag\u00e1ndose.&nbsp;<\/p>\n\n\n\n<p>Los inhibidores de puntos de control inmunitario (ICI) bloquean estas prote\u00ednas en los linfocitos T y las c\u00e9lulas cancerosas. Esto activa los linfocitos T y les permite destruir eficazmente las c\u00e9lulas cancerosas.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-immune-checkpoint-inhibitor-related-toxicity\"><span class=\"ez-toc-section\" id=\"What_Is_Immune-Checkpoint_Inhibitor-Related_Toxicity\"><\/span><strong>\u00bfQu\u00e9 es la toxicidad relacionada con los inhibidores de puntos de control inmunitario?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Si bien los inhibidores de puntos de control inmunitario (ICI) han tratado con \u00e9xito ciertos tipos de c\u00e1ncer, como el mieloma, el c\u00e1ncer de ri\u00f1\u00f3n o el c\u00e1ncer de pulm\u00f3n, en ocasiones pueden sobreestimular el sistema inmunitario, lo que provoca toxicidad relacionada con los inhibidores de puntos de control inmunitario o efectos adversos inmunitarios. La toxicidad se presenta de forma temprana y suele presentarse entre semanas y tres meses despu\u00e9s de iniciar el tratamiento con bloqueadores de puntos de control inmunitario.&nbsp;<\/p>\n\n\n\n<p>El tipo de ICI que recibi\u00f3 puede afectar y causar inflamaci\u00f3n en cualquier \u00f3rgano del cuerpo. Algunos de los \u00f3rganos afectados con efectos secundarios (<a href=\"https:\/\/www.mayoclinicproceedings.org\/article\/S0025-6196(19)30275-7\/fulltext\">toxicidades<\/a>) incluir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Piel (Dermatitis, observada en 40% a 60% de los casos)<\/li>\n\n\n\n<li>Pulmones (<a href=\"https:\/\/publications.ersnet.org\/content\/errev\/28\/154\/190012\">Neumonitis<\/a>, observado en el 5% de los casos)<\/li>\n\n\n\n<li>Sistema endocrino (hipotiroidismo, observado en el 61% de los casos)<\/li>\n\n\n\n<li>Sistema gastrointestinal (colitis grave, observada en el 2% al 7% de los casos)<\/li>\n\n\n\n<li>H\u00edgado (hepatitis, observada en el 5% al 10% de los casos)\u00a0<\/li>\n\n\n\n<li>Complicaciones neurol\u00f3gicas (Meningoencefalitis, <a href=\"https:\/\/ameripharmaspecialty.com\/es\/myasthenia-gravis\/myasthenia-gravis\/\">miastenia gravis<\/a>, y neuropat\u00eda perif\u00e9rica, observada en <a href=\"https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/14740338.2020.1738382\">1% a 5%<\/a> de casos)<\/li>\n<\/ul>\n\n\n\n<p>Cada paciente responde de forma diferente a la inmunoterapia con ICI. La toxicidad de los ICI puede variar entre pacientes con c\u00e1ncer y puede ir desde leve hasta gravemente mortal. Por lo tanto, se requiere un tratamiento est\u00e1ndar para controlar la toxicidad relacionada con los inhibidores de puntos de control inmunitario sin anular por completo su efecto en la lucha contra el c\u00e1ncer.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-is-immune-checkpoint-inhibitor-related-toxicity-managed\"><span class=\"ez-toc-section\" id=\"How_Is_Immune_Checkpoint_Inhibitor-Related_Toxicity_Managed\"><\/span><strong>\u00bfC\u00f3mo se maneja la toxicidad relacionada con los inhibidores de puntos de control inmunitario?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Los profesionales sanitarios tratan la toxicidad relacionada con los inhibidores de puntos de control inmunitario seg\u00fan su gravedad. Por ejemplo, los casos leves suelen tratarse con medidas de soporte y una monitorizaci\u00f3n estrecha. En la mayor\u00eda de los casos, se administran corticosteroides (p. ej., prednisona) para tratar los casos moderados a graves.&nbsp;<\/p>\n\n\n\n<p>En algunos casos, cuando los pacientes no responden a los esteroides, se utilizan medicamentos inmunosupresores como micofenolato de mofetilo o infliximab en el plan de tratamiento para estos pacientes.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-8185e7c162722a0f7ff8ca83abf8e09b\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tHabla con un especialista\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tAcerca de la asistencia para copagos\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Empezar<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-can-ivig-manage-immune-checkpoint-inhibitor-related-toxicity\"><span class=\"ez-toc-section\" id=\"How_Can_IVIG_Manage_Immune_Checkpoint_Inhibitor-Related_Toxicity\"><\/span><strong>\u00bfC\u00f3mo puede la IgIV controlar la toxicidad relacionada con los inhibidores de los puntos de control inmunitario?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La terapia con IgIV puede utilizarse como tratamiento adicional en algunos casos graves de toxicidad relacionada con inhibidores de puntos de control inmunitario. Por ejemplo, uno <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8670350\/\">informe de caso<\/a> Demostr\u00f3 que la terapia con esteroides en dosis altas y el tratamiento con IgIV resolvieron la toxicidad relacionada con los inhibidores del punto de control inmunitario en un paciente con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas no peque\u00f1as que experiment\u00f3 esofagitis, gastritis y miocarditis despu\u00e9s de tomar ICI (por ejemplo, pembrolizumab).&nbsp;<\/p>\n\n\n\n<p>La IgIV modula el sistema inmunol\u00f3gico sobreestimulado de m\u00faltiples maneras:&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-it-neutralizes-autoantibodies-nbsp\"><span class=\"ez-toc-section\" id=\"It_Neutralizes_Autoantibodies\"><\/span><strong>Neutraliza los autoanticuerpos&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>La terapia con IgIV neutraliza los autoanticuerpos producidos por los ICI debido a un sistema inmunitario sobreestimulado. Contrarresta los efectos de estos autoanticuerpos.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-it-reduces-inflammation\"><span class=\"ez-toc-section\" id=\"It_Reduces_Inflammation\"><\/span><strong>Reduce la inflamaci\u00f3n<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Dado que la IgIV tiene efectos antiinflamatorios, tambi\u00e9n ayuda a reducir la inflamaci\u00f3n causada por respuestas inmunol\u00f3gicas hiperactivas debido a los ICI.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-it-prevents-tissue-damage\"><span class=\"ez-toc-section\" id=\"It_Prevents_Tissue_Damage\"><\/span><strong>Previene el da\u00f1o tisular<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>La IgIV previene el da\u00f1o tisular al detener ataques inmunol\u00f3gicos adicionales.&nbsp;<\/p>\n\n\n\n<p>En resumen, la IgIV ayuda a los pacientes a controlar las toxicidades perjudiciales de los inhibidores de puntos de control inmunitario (ICI), a la vez que estabiliza el sistema inmunitario. Esto permite que los pacientes se beneficien de su tratamiento oncol\u00f3gico con ICI sin afectar su respuesta inmunitaria.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-when-is-ivig-used-for-immune-checkpoint-inhibitor-related-toxicity\"><span class=\"ez-toc-section\" id=\"When_Is_IVIG_Used_for_Immune_Checkpoint_Inhibitor-Related_Toxicity\"><\/span><strong>\u00bfCu\u00e1ndo se utiliza la IgIV para la toxicidad relacionada con los inhibidores de los puntos de control inmunitario?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"280\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-patient-1.jpg\" alt=\"Patient receiving IVIG at home\" class=\"wp-image-27042\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-patient-1.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-patient-1-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-patient-1-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-patient-1-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-patient-1-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-patient-1-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-patient-1-370x247.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>La IgIV no es un tratamiento de primera l\u00ednea para la toxicidad relacionada con los inhibidores de los puntos de control inmunitario y solo se recomienda en determinadas condiciones:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Cuando <a href=\"https:\/\/www.nature.com\/articles\/s41467-022-27960-2\">corticosteroides<\/a> u otros f\u00e1rmacos inmunosupresores no logran controlar la toxicidad relacionada con los inhibidores de los puntos de control inmunitario\u00a0<\/li>\n\n\n\n<li>Cuando ciertos pacientes no pueden tolerar altas dosis de esteroides debido a otras enfermedades<\/li>\n\n\n\n<li>Como tratamiento inmediato, en algunos casos raros pero graves, cuando los corticosteroides son insuficientes para controlar <a href=\"https:\/\/sciencedirect.com\/science\/article\/pii\/S0923753419421534\">ICI asociada con el s\u00edndrome de Stevens-Johnson (SSJ) y la necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET)<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-is-ivig-considered-for-immune-checkpoint-inhibitor-related-toxicity\"><span class=\"ez-toc-section\" id=\"Why_Is_IVIG_Considered_for_Immune_Checkpoint_Inhibitor-Related_Toxicity\"><\/span><strong>\u00bfPor qu\u00e9 se considera la IgIV en casos de toxicidad relacionada con los inhibidores de puntos de control inmunitario?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La IgIV se considera para la toxicidad relacionada con los inhibidores de puntos de control inmunitario por dos razones principales:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>En primer lugar, la IgIV tiene una respuesta r\u00e1pida, lo que significa que act\u00faa r\u00e1pidamente y puede controlar toxicidades graves o refractarias relacionadas con los ICI.\u00a0<\/li>\n\n\n\n<li>En segundo lugar, la IgIV se dirige a partes espec\u00edficas del sistema inmunitario y no interfiere con la eficacia de los ICI, a diferencia de otros f\u00e1rmacos inmunosupresores.\u00a0<\/li>\n<\/ul>\n\n\n\n<div  id=\"call-to-action-4326b490f70646812cab7f28f30491dd\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga autorizaci\u00f3n previa para IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-the-standard-dose-of-ivig-for-immune-checkpoint-inhibitor-related-toxicity\"><span class=\"ez-toc-section\" id=\"What_Is_the_Standard_Dose_of_IVIG_for_Immune_Checkpoint_Inhibitor-Related_Toxicity\"><\/span><strong>\u00bfCu\u00e1l es la dosis est\u00e1ndar de IgIV para la toxicidad relacionada con los inhibidores de puntos de control inmunitario?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La dosis de IgIV puede variar entre los pacientes y el tipo de toxicidad que experimenten. Por ejemplo, las inmunoglobulinas intravenosas pueden administrarse en una dosis de <a href=\"https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2017.77.6385\">2 g\/kg (0,4 g\/kg\/d\u00eda durante 5 d\u00edas)<\/a> para tratar la necr\u00f3lisis epid\u00e9rmica t\u00f3xica inducida por ICI (un tipo de afecci\u00f3n de la piel), <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213007119300218\">neumonitis<\/a> (un tipo de enfermedad pulmonar), <a href=\"https:\/\/ameripharmaspecialty.com\/es\/myasthenia-gravis\/myasthenia-gravis\/\">miastenia gravis<\/a>, y <a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-guillain-barre-syndrome\/\">S\u00edndrome de Guillain-Barr\u00e9<\/a>.&nbsp;<\/p>\n\n\n\n<p>Los pacientes que recibieron tratamiento con IgIV mostraron una mejor\u00eda significativa de su condici\u00f3n. Sin embargo, la IgIV puede causar algunos <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-common-side-effects-of-ivig-treatment\/\">efectos secundarios<\/a>, como dolor de cabeza, fiebre, n\u00e1useas y reacciones al\u00e9rgicas.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusi\u00f3n<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Aunque los inhibidores de puntos de control inmunitario (ICI) se consideran eficaces para tratar c\u00e1nceres agresivos, tambi\u00e9n causan toxicidades (efectos secundarios) en algunos pacientes al sobreestimular el sistema inmunitario.&nbsp;<\/p>\n\n\n\n<p>Si usted o un ser querido experimentan s\u00edntomas inusuales o toxicidad asociada a los ICI, la terapia con IgIV puede ayudar a controlar estas toxicidades. La IgIV logra esto modulando el sistema inmunitario hiperactivo sin interrumpir el mecanismo de acci\u00f3n de los ICI en la lucha contra el c\u00e1ncer.&nbsp;<\/p>\n\n\n\n<p>Se recomienda consultar a su proveedor de atenci\u00f3n m\u00e9dica para obtener un plan personalizado de IgIV seg\u00fan su toxicidad relacionada con ICI.<\/p>","protected":false},"excerpt":{"rendered":"<p>Los inhibidores de puntos de control inmunitario (ICI) son potentes f\u00e1rmacos que estimulan respuestas inmunitarias duraderas contra el c\u00e1ncer. La inmunoterapia con ICI ha revolucionado los procedimientos de tratamiento del c\u00e1ncer y se ha convertido en una opci\u00f3n eficaz para pacientes con c\u00e1nceres avanzados o de dif\u00edcil tratamiento (agresivos).\u00a0<\/p>","protected":false},"author":7,"featured_media":27041,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[7],"tags":[8],"class_list":["post-27038","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ivig","tag-dr-christine-leduc"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IVIG for Immune Checkpoint Inhibitor-Related Toxicity - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"This article explains what immune checkpoint inhibitors are, the toxicities they cause, and how IVIG therapy can help manage them.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIG for Immune Checkpoint Inhibitor-Related Toxicity - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"This article explains what immune checkpoint inhibitors are, the toxicities they cause, and how IVIG therapy can help manage them.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-28T00:30:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-28T00:30:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Christine Leduc, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Christine Leduc, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/\"},\"author\":{\"name\":\"Dr. Christine Leduc, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/person\\\/0d161a7a3c2b0cf54ab0cf25c936dd87\"},\"headline\":\"IVIG for Immune Checkpoint Inhibitor-Related Toxicity\",\"datePublished\":\"2024-12-28T00:30:09+00:00\",\"dateModified\":\"2024-12-28T00:30:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/\"},\"wordCount\":989,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/ivig-at-home.jpg\",\"keywords\":[\"Dr. Christine Leduc\"],\"articleSection\":[\"IVIG\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/\",\"name\":\"IVIG for Immune Checkpoint Inhibitor-Related Toxicity - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/ivig-at-home.jpg\",\"datePublished\":\"2024-12-28T00:30:09+00:00\",\"dateModified\":\"2024-12-28T00:30:12+00:00\",\"description\":\"This article explains what immune checkpoint inhibitors are, the toxicities they cause, and how IVIG therapy can help manage them.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/ivig-at-home.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/ivig-at-home.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Patient receiving IVIG at home for Immune checkpoint inhibitor-related Toxicity\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/ivig\\\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIG for Immune Checkpoint Inhibitor-Related Toxicity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/person\\\/0d161a7a3c2b0cf54ab0cf25c936dd87\",\"name\":\"Dr. Christine Leduc, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"caption\":\"Dr. Christine Leduc, PharmD\"},\"description\":\"Dr. Christine Leduc, PharmD, was born and raised in Irvine, CA. She attended college at Midwestern University, where she graduated cum laude. The most rewarding part of her job is suggesting lifestyle changes, educating patients on how their medication works, and precepting future pharmacists. Her areas of expertise are customer service and knowledge of specialty medication. Having worked in the service industry in the past, she has gained the customer service skills necessary to understand the needs of her patients. Dr. Leduc is currently precepting students from Marshall B. Ketchum University, University of Kansas, and Midwestern University. In her free time, she enjoys traveling, baking, and gardening. See Author Biography\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/christine-leduc\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgIV para la toxicidad relacionada con los inhibidores de los puntos de control inmunitario - AmeriPharma\u00ae Atenci\u00f3n especializada","description":"Este art\u00edculo explica qu\u00e9 son los inhibidores de puntos de control inmunitario, las toxicidades que causan y c\u00f3mo la terapia con IgIV puede ayudar a controlarlos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/","og_locale":"es_MX","og_type":"article","og_title":"IVIG for Immune Checkpoint Inhibitor-Related Toxicity - AmeriPharma\u00ae Specialty Care","og_description":"This article explains what immune checkpoint inhibitors are, the toxicities they cause, and how IVIG therapy can help manage them.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2024-12-28T00:30:09+00:00","article_modified_time":"2024-12-28T00:30:12+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg","type":"image\/jpeg"}],"author":"Dr. Christine Leduc, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Christine Leduc, PharmD","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/"},"author":{"name":"Dr. Christine Leduc, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/person\/0d161a7a3c2b0cf54ab0cf25c936dd87"},"headline":"IVIG for Immune Checkpoint Inhibitor-Related Toxicity","datePublished":"2024-12-28T00:30:09+00:00","dateModified":"2024-12-28T00:30:12+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/"},"wordCount":989,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg","keywords":["Dr. Christine Leduc"],"articleSection":["IVIG"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/","url":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/","name":"IgIV para la toxicidad relacionada con los inhibidores de los puntos de control inmunitario - AmeriPharma\u00ae Atenci\u00f3n especializada","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg","datePublished":"2024-12-28T00:30:09+00:00","dateModified":"2024-12-28T00:30:12+00:00","description":"Este art\u00edculo explica qu\u00e9 son los inhibidores de puntos de control inmunitario, las toxicidades que causan y c\u00f3mo la terapia con IgIV puede ayudar a controlarlos.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg","width":1280,"height":853,"caption":"Patient receiving IVIG at home for Immune checkpoint inhibitor-related Toxicity"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/zh\/ivig\/ivig-for-immune-checkpoint-inhibitor-related-toxicity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"IVIG for Immune Checkpoint Inhibitor-Related Toxicity"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#website","url":"https:\/\/ameripharmaspecialty.com\/vi\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/vi\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/vi\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/person\/0d161a7a3c2b0cf54ab0cf25c936dd87","name":"Dra. Christine Leduc, PharmD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","caption":"Dr. Christine Leduc, PharmD"},"description":"La Dra. Christine Leduc, doctora en farmacia, naci\u00f3 y creci\u00f3 en Irvine, California. Curs\u00f3 estudios universitarios en la Universidad Midwestern, donde se gradu\u00f3 con honores. Lo m\u00e1s gratificante de su trabajo es sugerir cambios en el estilo de vida, educar a los pacientes sobre el funcionamiento de sus medicamentos y ser tutora de futuros farmac\u00e9uticos. Sus \u00e1reas de especializaci\u00f3n son la atenci\u00f3n al cliente y el conocimiento de medicamentos especializados. Tras haber trabajado en el sector servicios, ha adquirido las habilidades de atenci\u00f3n al cliente necesarias para comprender las necesidades de sus pacientes. Actualmente, la Dra. Leduc imparte clases a estudiantes de la Universidad Marshall B. Ketchum, la Universidad de Kansas y la Universidad Midwestern. En su tiempo libre, disfruta de viajar, la reposter\u00eda y la jardiner\u00eda. Ver biograf\u00eda de la autora.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Christine Leduc, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"},"uagb_comment_info":0,"uagb_excerpt":"Immune checkpoint inhibitors (ICIs) are potent drug agents that stimulate long-lasting immune responses against cancer. ICI immunotherapy has revolutionized treatment procedures for cancer and now has become an effective option for patients with advanced or hard-to-treat (aggressive) cancers.\u00a0","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/ivig-at-home.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Christine Leduc, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/ivig\/\" rel=\"category tag\">IVIG<\/a>","rttpg_excerpt":"Immune checkpoint inhibitors (ICIs) are potent drug agents that stimulate long-lasting immune responses against cancer. ICI immunotherapy has revolutionized treatment procedures for cancer and now has become an effective option for patients with advanced or hard-to-treat (aggressive) cancers.\u00a0","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=27038"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27038\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/27041"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=27038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=27038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=27038"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}